Key Insights

Highlights

Success Rate

81% trial completion

Published Results

23 trials with published results (20%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

9.7%

11 terminated out of 113 trials

Success Rate

81.0%

-5.5% vs benchmark

Late-Stage Pipeline

14%

16 trials in Phase 3/4

Results Transparency

49%

23 of 47 completed with results

Key Signals

23 with results81% success11 terminated

Data Visualizations

Phase Distribution

86Total
Not Applicable (13)
Early P 1 (5)
P 1 (12)
P 2 (40)
P 3 (13)
P 4 (3)

Trial Status

Completed47
Recruiting26
Unknown11
Terminated11
Active Not Recruiting6
Not Yet Recruiting5

Trial Success Rate

81.0%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (113)

Showing 20 of 20 trials
NCT06672822Phase 2Recruiting

Intralesional Injection of STS in Treatment of Calcinosis

NCT01276470Recruiting

Environmental Risk Factors for the Anti-synthetase Syndrome

NCT06808672Active Not RecruitingPrimary

Biomarkers of Cancer-Associated Myositis

NCT01734369CompletedPrimary

Environmental Risk Factors for Myositis in Military Personnel

NCT07558850Not ApplicableRecruiting

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

NCT00017914RecruitingPrimary

Adult and Juvenile Myositis

NCT06154252Phase 2Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT05979441Phase 3Enrolling By Invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT07486869Phase 2Not Yet RecruitingPrimary

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

NCT01432613Not ApplicableCompleted

Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies

NCT02945345RecruitingPrimary

Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

NCT06698796Phase 3RecruitingPrimary

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

NCT05027152Not ApplicableCompleted

Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties

NCT05832034Phase 2Active Not Recruiting

Add-on Intravenous Immunoglobulins in Early Myositis

NCT00341679Completed

Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

NCT04402086Recruiting

Rheumatology Patient Registry and Biorepository

NCT07403188Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07377058Not ApplicableRecruitingPrimary

RCT of Tocilizumab for Anti-MDA5+DM

NCT07374107Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

Scroll to load more

Research Network

Activity Timeline